Wednesday, September 23 – Viking Therapeutics’ VK2735 met Truist’s “best-case scenario,” with robust weight loss that was largely maintained when patients transitioned to less frequent dosing. Viking’s stock popped more than 30% on Tuesday.

Wednesday, September 23 – With sales of the oral GLP-1 medicine rising quickly, executives reassured investors that Novo has secured production capacity to support continued growth.

Wednesday, September 23 – With a trillion-dollar market cap and a wildly successful GLP-1 portfolio, Eli Lilly isn’t resting on its laurels. At the Psych Congress 2026, the company presented early-stage data that could support the potential of its next-gen GLP-1 and GIP receptor agonist to treat diseases far beyond obesity.

Wednesday, September 23 – (MedPage Today) — Note that some links may require registration or subscription.
Dozens of Americans sued manufacturers of GLP-1 receptor agonists, claiming the drugmakers failed to warn patients about the risk of non-arteritic anterior ischemic…

Wednesday, September 23 – The mid-stage readout is one link in a chain of catalysts that analysts were watching for this year from Roche’s metabolic pipeline, which features assets from the $2.7 billion acquisition of Carmot Therapeutics as well as partner Zealand Pharma.

Wednesday, September 23 – Heidi Skolnik, a sports nutritionist, exercise physiologist and bestselling author, joins TODAY to discuss her latest book, “Your GLP-1 Game Plan,” that is filled with guidance on what to eat and how to move and thrive on weight loss medications. “The medication doesn’t give you nourishment, and it doesn’t give you strength. You really need to go beyond the scale to think about your ‘why.’ And we know that when you focus on health beyond appearance, you do better,” she says.

Tuesday. September 22 – Hundreds of Americans are suing GLP-1 drugmakers Novo Nordisk and Ely Lilly, saying they were not adequately warned of the potential danger of vision loss. In statements, Novo Nordisk says, in part, they are “vigorously” fighting the lawsuits, saying they are “without merit,” while Eli Lilly says in part, it maintains “patient safety” is its “top priority.” NBC News’ Stephanie Gosk has the story.

Tuesday. September 22 – Children prescribed GLP-1 medications for weight loss, prediabetes or type 2 diabetes are at risk for nutritional deficiencies—diagnosed in nearly one in six patients (16.8%) within the first year—according to a new study published in the journal Childhood Obesity. Vitamin D deficiency was the most common, identified in 12.4% of children within one year of GLP-1 treatment.

Tuesday, September 22 – GLP-1 drugs have revolutionized obesity treatment, but they can lead people to lose muscle mass along with fat. And when patients stop treatment, they often regain their weight—primarily as fat.

Tuesday, September 22 – A large study suggests the cardiovascular benefits of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound can disappear surprisingly quickly when treatment stops. After two years off the medications, patients had a 22% higher risk of heart attack, stroke, and death compared with those who stayed on them.

Saturday, September 19 – Research shows that microdosing GLP-1 medications may still lead to weight loss. Tatsiana Volkava · Moment/Getty

Recent research suggests that people may still lose weight while staying on the lowest starting doses of GLP-1 medications, such as Wegovy or Zepbound, for longer periods.

After one year, people taking sustained low dose tirzepatide lost about 5.5% of their body weight, while those taking sustained low dose semaglutide lost about 2.2%.

Lower doses were associated with more modest weight loss than higher doses, but sustained low dose semaglutide was also associated with lower rates of some side effects.

Saturday, September 19 – (MedPage Today) — Frailty did not appear to prevent adults with cardiovascular disease and overweight or obesity from reaping the benefits of semaglutide (Wegovy), a secondary analysis of SELECT trial data indicated.
By week 104, semaglutide…

Saturday, September 19 – Ozempic and other GLP-1 medications can improve blood sugar, weight, and cardiovascular health, but researchers found little evidence that they also improve mental health, employment, marriage, or overall well-being. The findings suggest the drugs’ broader life effects may be subtler than their dramatic physical health benefits.

Friday, September 18 – Millions of people worldwide—as many as 1 in 8 adults in the U.S.—are taking GLP-1 medications, such as Ozempic, Mounjaro, Wegovy and Zepbound, to treat diabetes or for weight loss.

Thursday, September 17 – Retatrutide, an experimental weight loss drug still undergoing clinical trials at Eli Lily, is being marketed online and illegally sold to U.S. clients, a CBS News investigation found. CBS News investigative reporter and producer Daniel Gilbert has the story.

An Illinois federal judge is weighing whether the state’s genetic privacy law protects against disclosing information about people who have taken genetic tests, with a DNA testing company accused of unlawfully sharing such information with Google arguing Wednesday the statute applies only to disclosure of actual test results.

Thursday, September 17 – Elvinix Inc. has announced an exclusive license agreement with Zealand Pharma A/S granting Elvinix the rights to develop and commercialize Zealand’s GLP-1/gastrin dual-agonist peptide portfolio.

Wednesday, September 16 – (MedPage Today) — An international consensus panel outlined the first clinical framework for implementing general-population screening for islet autoantibodies to catch early-stage type 1 diabetes. (Diabetologia)
Another international consensus…

Tuesday, September 15 – (MedPage Today) — Blockbuster GLP-1 receptor agonists revolutionized obesity management in recent years, driving weight loss of up to 20%.
This weight loss, however, can carry a notable downside: Studies estimate that 15% to 40% of GLP-1-induced…

Tuesday, September 15 – The one health care policy Republicans agree on, and a look at how rural providers are approaching AI.

Monday, September 14 – A study linked 15 cases of Wernicke encephalopathy to GLP-1 drugs like Ozempic and Mounjaro, raising concerns about vitamin B1 deficiency risks.

AI analysis of 400,000 Reddit posts found that users of drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound reported unexpected symptoms including menstrual changes, chills, hot flashes, and fatigue. Researchers cannot say the medications caused these problems, but the patterns may reveal overlooked signals worth studying.

GLP-1 drugs such as Ozempic, Wegovy, and Zepbound may increase hair-loss risk by 7% in men who are already genetically susceptible to male-pattern baldness. The findings suggest thinning hair may not be caused only by rapid weight loss and could also reflect a biological link between GLP-1 activity and hair follicles.

Sunday, September 13 – Semaglutide helped older healthy mice live longer while improving memory, muscle function, blood sugar control, and several biological signs of aging. Its effects went beyond those seen with calorie restriction, raising the possibility that GLP-1 drugs could tap into a separate biological pathway linked to longevity.

Saturday, September 12 – Do you gain weight once you stop using them? Do they make your face saggy? Can they improve your mental health? Experts explain whether 13 common beliefs about GLP-1s are true or falseFALSE “GLP-1 medications mimic Glucagon-like peptide-1 – one of the hormones involved in appetite regulation. It doesn’t completely suppress hunger, but it is powerful,” says Dr Federica Amati, nutrition lead at Imperial College School of Medicine and author of The Appetite Reset. “The medicine is about 1,000 times stronger than what we naturally produce from our gut,” she explains. As food passes through the gut, cells called L-cells sense the nutrients, which sparks the production of the GLP-1 hormone.

Friday, September 11 – As weight loss drugs have risen all around the world, it has reshaped users’ relationships for better and for worseAs GLP-1 use continues to rise in the US and the UK, people’s bodies are being reshaped – as are their relationships.“Relationships tend to develop a sense of equilibrium and predictability over time,” says Dr Lindsey Berisha, a licensed clinical psychologist who has worked with clients using GLP-1s for over 10 years. “When one partner undergoes a significant change, it can shift that equilibrium, and even positive change can create uncertainty for both partners.” Continue reading…

Thursday, September 10 – Watch this discussion on how GLP-1 drugs for obesity are changing the shape of U.S. healthcare. From direct-to-consumer portals to pharmacy deals, how these drugs reach patients is changing—and leading to debates over pricing and coverage. Learn how your company can be both patient-forward while also maximizing revenue in this unique environment.

Thursday, September 10 – Semaglutide, the drug found in Ozempic and Wegovy, was linked to nearly 40% fewer asthma attacks in a large real-world study. It was also associated with about 20% fewer COPD flare-ups. Researchers say GLP-1 drugs may offer respiratory benefits in addition to their effects on diabetes and obesity, but clinical trials are needed to confirm the findings.

Thursday, September 10 – A CDC Covid restructuring, public trust in Fauci, and more health news from Morning Rounds

Thursday, September 10 – (MedPage Today) — Growing evidence linked GLP-1 drugs to a reduced risk of exacerbations of two types of chronic airways disease: asthma and chronic obstructive pulmonary disease (COPD).
Based on real-world records from the U.K., affected patients…

Thursday, September 10 – (MedPage Today) — Men predisposed to androgenetic alopecia had a higher risk of hair loss when using GLP-1 drugs, a Mendelian randomization study suggested. (Journal of Investigative Dermatology)
Truveta data indicated a 19% increase in GLP-1…

Thursday, September 10 – Gan & Lee Pharmaceuticals Co. Ltd. has signed its largest ex-China licensing agreement for obesity candidate bofanglutide (GZR-18), granting Menarini Group rights across 39 European countries in a deal worth up to €726 million (US$844 million). Bofanglutide is a biweekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) independently discovered and developed by Beijing-based Gan & Lee.

Wednesday, September 9 – Structure Therapeutics’ oral GLP-1 candidate aleniglipron showed 72-week efficacy “in line” with Novo Nordisk’s oral Wegovy, BMO Capital Markets wrote in a note to investors. Meanwhile, Structure’s amylin and calcitonin receptor agonist ACCG-2671 showed “impressive” target engagement in a Phase 1 trial of healthy volunteers, according to Leerink Partners.

Wednesday, September 9 – Semaglutide, the drug behind Ozempic and Wegovy, may have benefits that extend well beyond weight loss and diabetes. In a large Swedish study of nearly 15,000 people with bipolar disorder, its use was linked to a 21% lower risk of psychiatric hospitalization. Researchers think effects on inflammation and brain-related biological pathways could help stabilize mood, though other GLP-1 drugs did not show the same association.

Wednesday, September 9 – The diabetes and weight-loss injection semaglutide can reduce asthma attacks by up to 40%, according to research presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain. The study was led by Chloe Bloom, clinical associate professor in respiratory epidemiology at the National Heart & Lung Institute, Imperial College London, UK, and presented by Dr. Bohee Lee.

Sunday, September 6 – A new review found that GLP-1s offer significant improvements in obstructive sleep apnea associated with obesity. vitapix/E+/Getty Images

New research has found that GLP-1 drugs may improve obstructive sleep apnea (OSA) related to obesity.

The effects of tirzepatide (Zepound), which is FDA approved for OSA, were especially notable.

GLP-1s appear to improve OSA associated with obesity by promoting fat loss in the neck, throat, and tongue.

CPAP therapy should be continued until a physician has confirmed remission with a sleep study.

Sunday, September 6 – (MedPage Today) — GLP-1 receptor agonists may be powerful tools for treating obesity and cardiometabolic disease, but relying on medications alone risks overlooking the forces helping drive the obesity epidemic, according to Laura Schmidt, PhD…

Sunday, September 6 – Gan & Lee Pharmaceuticals Co. Ltd. has signed its largest ex-China licensing agreement for obesity candidate bofanglutide (GZR-18), granting Menarini Group rights across 39 European countries in a deal worth up to €726 million (US$844 million). Bofanglutide is a biweekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) independently discovered and developed by Beijing-based Gan & Lee.

Saturday, September 5 – (MedPage Today) — Prescribing GLP-1 receptor agonists to children ages 8 to 11 years with obesity surged 310-fold since 2019, despite a lack of FDA approval in kids under 12, a large cross-sectional analysis showed.
Among over 3.5 million children…

Saturday, September 5 – Although the number of U.S. children under age 12 with obesity who are prescribed the weight-loss drugs Saxenda, Wegovy and Zepbound remains low, it was 310 times higher in June 2026 than in 2019, when the drugs were first prescribed, a new study shows.